AlphaGrep UK’s AbbVie ABBV Stock Holding History

AlphaGrep UK’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-860	Closed	-$216K	–	729
2026 Q2	$216K	Sell	860 -539	-39%	-$116K	0.06%	661
2026 Q1	$304K	Sell	1,399 -1,741	-55%	-$386K	0.09%	499
2025 Q4	$717K	Buy	+3,140	New	+$715K	0.24%	96

Other funds holding ABBV

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

AlphaGrep UK's ABBV Position: Q3 2026 in Review

AlphaGrep UK sold out of AbbVie (ABBV) in Q3 2026, closing a stake of 860 shares — an estimated $216K sold.

AlphaGrep UK first reported a position in ABBV in Q4 2025 and held it in 3 quarters. The position peaked at $717K in Q4 2025. 3,830 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

AlphaGrep UK reported no remaining AbbVie position as of Q3 2026 after selling out during the quarter.
AlphaGrep UK sold 860 AbbVie shares in Q3 2026, an estimated $216K.
AlphaGrep UK first reported a position in AbbVie in Q4 2025 and held it in 3 quarters.
AlphaGrep UK's AbbVie position peaked at $717K in Q4 2025.
3,830 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on AlphaGrep UK's 13F filing for Q3 2026, filed 12 Nov 2026.